(Q36998032)

17 August 2017

1 reference

title

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review (English)

1 reference

17 August 2017

1 reference

1

Alma Tostmann

1 reference

17 August 2017

2

Martin J Boeree

1 reference

17 August 2017

Rob E Aarnoutse

3

1 reference

17 August 2017

Wiel C M de Lange

series ordinal

4

1 reference

17 August 2017

Andre J A M van der Ven

series ordinal

5

1 reference

17 August 2017

Richard Dekhuijzen

series ordinal

6

1 reference

17 August 2017

6 November 2007

1 reference

Journal of Gastroenterology and Hepatology

17 August 2017

1 reference

17 August 2017

23

1 reference

17 August 2017

2

1 reference

17 August 2017

192-202

1 reference

An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment

17 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Criteria of drug-induced liver disorders. Report of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Liver injury during antituberculosis treatment: an 11-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Frequency and type of reactions to antituberculosis drugs: observations in routine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Evaluation of patient-related factors associated with causality, preventability, predictability and severity of hepatotoxicity during antituberculosis [correction of antituberclosis] treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Toxic hepatitis with isoniazid and rifampin. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

A model of isoniazid-induced hepatotoxicity in rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Effect of rifampicin on liver function in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Hepatic side-effects of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Drug-induced hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Idiosyncratic drug reactions: the reactive metabolite syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Isoniazid and Iproniazid: Activation of Metabolites to Toxic Intermediates in Man and Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Factors in hydrazine formation from isoniazid by paediatric and adult tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

THE PATHOLOGICAL ANATOMY OF HYDRAZINE POISONING.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Oxidative stress: from basic research to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Interaction of rifampicin with other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Clinical pharmacokinetics of the antituberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Adverse reactions to rifampicin in antituberculosis regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Effect of age and gender on the activity of human hepatic CYP3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Tuberculosis management in EuropeRecommendations of a Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Drug-related hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

An official ATS statement: hepatotoxicity of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Tuberculosis drug development pipeline: progress and hope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Levofloxacin treatment of active tuberculosis and the risk of adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Therapeutic drug monitoring in the treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.05207.X

10.1111/J.1440-1746.2007.05207.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference